PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on central sexual-response pathways rather than the vascular system. It is FDA-approved…
Melanocortin-receptor agonist studied for sexual-response pathways.
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on central sexual-response pathways rather than the vascular system. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
PT-141 is a synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the central nervous system. Unlike PDE5 inhibitors, it works upstream of the vascular response.
Agonist at melanocortin receptors (MC3R/MC4R) in the central nervous system, modulating sexual-response circuits.
| Property | Detail |
|---|---|
| Class | Melanocortin receptor agonist |
| Sequence length | 7 amino acids |
| Half-life | ~2 hours |
| FDA status | Approved as Vyleesi for HSDD (premenopausal women) |
Reported half-life: ~2 hours.
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
This reference page was last reviewed on 2026-06-13 by the Clarity Wellness editorial team.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
PDE5 inhibitors (sildenafil, tadalafil) work on the vascular response. PT-141 acts upstream in the central nervous system on melanocortin receptors.